RA CAPITAL MANAGEMENT, L.P.
- SEC CIK
- 0001346824
Holdings, Q2 2026
Positions as of Jun 30, 2026, filed Aug 14, 2026.SEC
- Positions
- 84
- −1 vs. Q1 2026
- Total value
- $11.51B
- +$2.07B (+21.9%) vs. Q1 2026
Compare with Q1 2026: new, added, reduced and sold out
Positions
Long positions only. Changes compare share counts with Q1 2026.
| Security | Class | Shares | Value | % of portfolio | Change in shares | Action | History |
|---|---|---|---|---|---|---|---|
| ASNDASCENDIS PHARMA A/S | ORD SHS | 10,281,496 | $2.74B | 23.83% | +10,281,496 | New | View |
| PBLSPARABILIS MEDICINES INC COM | Stock | 28,933,371 | $791.91M | 6.88% | +28,933,371 | New | View |
| RYTMRHYTHM PHARMACEUTICALS INC | COM | 6,666,837 | $740.22M | 6.43% | 00.0% | Unchanged | View |
| PCVXVAXCYTE INC | COM | 11,474,599 | $667.02M | 5.80% | 00.0% | Unchanged | View |
| SIONSIONNA THERAPEUTICS INC | COM | 9,905,045 | $435.72M | 3.79% | 00.0% | Unchanged | View |
| TYRATYRA BIOSCIENCES INC | COM | 12,198,625 | $389.62M | 3.39% | 00.0% | Unchanged | View |
| EWTXEDGEWISE THERAPEUTICS INC | COM | 8,392,730 | $341M | 2.96% | −2,035,707−19.5% | Reduced | View |
| NAMSNEWAMSTERDAM PHARMA COMPANY | ORDINARY SHARES | 9,550,191 | $323.66M | 2.81% | 00.0% | Unchanged | View |
| COAGHEMAB THERAPEUTICS HLDGS INC | COM SHS | 7,808,627 | $286.81M | 2.49% | +7,808,627 | New | View |
| SEPNSEPTERNA INC | COM | 6,995,858 | $234.29M | 2.04% | 00.0% | Unchanged | View |
| BCAXBICARA THERAPEUTICS INC | COM | 7,255,993 | $215.43M | 1.87% | 00.0% | Unchanged | View |
| MLYSMINERALYS THERAPEUTICS INC | COM | 7,692,750 | $207.55M | 1.80% | 00.0% | Unchanged | View |
| GHRSGH RESEARCH PLC | ORDINARY SHARES | 7,636,813 | $205.28M | 1.78% | −39,884−0.5% | Reduced | View |
| IRONDISC MEDICINE INC | COM | 2,450,221 | $179.21M | 1.56% | 00.0% | Unchanged | View |
| SGPSPYGLASS PHARMA INC | COM SHS | 8,021,117 | $178.55M | 1.55% | 00.0% | Unchanged | View |
| ARTVARTIVA BIOTHERAPEUTICS INC | COM | 17,955,642 | $174.17M | 1.51% | +8,102,340+82.2% | Added | View |
| JANXJANUX THERAPEUTICS INC | COM | 11,189,693 | $171.87M | 1.49% | 00.0% | Unchanged | View |
| TSHATAYSHA GENE THERAPIES INC | COM SHS | 23,555,648 | $160.41M | 1.39% | 00.0% | Unchanged | View |
| BCRXBIOCRYST PHARMACEUTICALS INC | COM | 15,827,186 | $158.27M | 1.38% | 00.0% | Unchanged | View |
| WVEWAVE LIFE SCIENCES LTD | SHS | 26,975,505 | $156.73M | 1.36% | 00.0% | Unchanged | View |
| NUVALENT INC670703107 | COM | 1,246,456 | $153.94M | 1.34% | −1,287,689−50.8% | Reduced | – |
| ABVXABIVAX SA | SPONSORED ADS | 1,132,557 | $150.92M | 1.31% | +1,132,557 | New | View |
| ORKAORUKA THERAPEUTICS INC | COM | 1,554,597 | $147.95M | 1.29% | +1,554,597 | New | View |
| CLYMCLIMB BIO INC | COM | 11,300,939 | $147.36M | 1.28% | 00.0% | Unchanged | View |
| SLDBSOLID BIOSCIENCES INC | COM NEW | 12,036,126 | $120.24M | 1.04% | +2,696,148+28.9% | Added | View |
| ZLABZAI LAB LTD | ADR | 5,743,533 | $109.13M | 0.95% | +36,271+0.6% | Added | View |
| SPRYARS PHARMACEUTICALS INC | COM | 10,860,977 | $87M | 0.76% | 00.0% | Unchanged | View |
| XNCRXENCOR INC | COM | 5,274,274 | $84.92M | 0.74% | +377,037+7.7% | Added | View |
| JBIOJADE BIOSCIENCES INC | COM NEW | 3,671,083 | $81.57M | 0.71% | 00.0% | Unchanged | View |
| NTLAINTELLIA THERAPEUTICS INC | COM | 4,526,926 | $76.6M | 0.67% | +4,526,926 | New | View |
| LBRXLB PHARMACEUTICALS INC | COM SHS | 2,208,604 | $71.68M | 0.62% | 00.0% | Unchanged | View |
| DFTXDEFINIUM THERAPEUTICS INC | COM SHS | 1,500,000 | $70.56M | 0.61% | +1,500,000 | New | View |
| ACRSACLARIS THERAPEUTICS INC | COM | 12,723,026 | $67.3M | 0.58% | +5,918,954+87.0% | Added | View |
| FDMT4D MOLECULAR THERAPEUTICS IN | COM | 5,049,779 | $67.16M | 0.58% | 00.0% | Unchanged | View |
| SANASANA BIOTECHNOLOGY INC | COM | 18,750,000 | $65.44M | 0.57% | +18,750,000 | New | View |
| DMRADAMORA THERAPEUTICS INC | COM NEW | 2,399,702 | $62.42M | 0.54% | +3920.0% | Added | View |
| MNPRMONOPAR THERAPEUTICS INC | COM NEW | 667,207 | $61.78M | 0.54% | 00.0% | Unchanged | View |
| ABOSACUMEN PHARMACEUTICALS INC | COM | 20,992,669 | $56.05M | 0.49% | 00.0% | Unchanged | View |
| GERNGERON CORP | COM | 42,809,751 | $54.8M | 0.48% | −20,961,615−32.9% | Reduced | View |
| RZLTREZOLUTE INC | COM NEW | 9,445,039 | $49.11M | 0.43% | +265,039+2.9% | Added | View |
| EVMNEVOMMUNE INC | COM SHS | 3,494,638 | $46.44M | 0.40% | 00.0% | Unchanged | View |
| VORVOR BIOPHARMA INC | COM NEW | 2,402,095 | $44.22M | 0.38% | −3,002,903−55.6% | Reduced | View |
| IPSCCENTURY THERAPEUTICS INC | COM | 17,754,430 | $43.5M | 0.38% | 00.0% | Unchanged | View |
| AKTSAKTIS ONCOLOGY INC | COM | 1,314,405 | $42.36M | 0.37% | −188,679−12.6% | Reduced | View |
| BIOABIOAGE LABS INC | COM | 1,671,648 | $40.97M | 0.36% | +21,000+1.3% | Added | View |
| CCCCC4 THERAPEUTICS INC | COM STK | 8,000,000 | $37.36M | 0.32% | 00.0% | Unchanged | View |
| MIRMMIRUM PHARMACEUTICALS INC | COM | 318,554 | $37.29M | 0.32% | 00.0% | Unchanged | View |
| CAPRCAPRICOR THERAPEUTICS INC | COM NEW | 1,507,844 | $36.31M | 0.32% | 00.0% | Unchanged | View |
| PEPGPEPGEN INC | COM | 20,064,545 | $36.12M | 0.31% | 00.0% | Unchanged | View |
| PRLDPRELUDE THERAPEUTICS INC | COM | 6,475,882 | $34.52M | 0.30% | +6,475,882 | New | View |
| NKTXNKARTA INC | COM | 10,805,129 | $30.58M | 0.27% | 00.0% | Unchanged | View |
| QTTBQ32 BIO INC | COM | 2,332,457 | $29.72M | 0.26% | +2,332,457 | New | View |
| AVRANTERIS TECHNOLOGIES GLOBAL | COM | 3,000,000 | $29.55M | 0.26% | 00.0% | Unchanged | View |
| EDITEDITAS MEDICINE INC | COM | 8,889,000 | $28.8M | 0.25% | +8,889,000 | New | View |
| OVIDOVID THERAPEUTICS INC | COM | 10,500,968 | $28.25M | 0.25% | −213,032−2.0% | Reduced | View |
| ASMBASSEMBLY BIOSCIENCES INC | COM NEW | 1,020,410 | $28.04M | 0.24% | 00.0% | Unchanged | View |
| ALXOALX ONCOLOGY HLDGS INC | COM | 13,011,849 | $26.93M | 0.23% | 00.0% | Unchanged | View |
| BNTCBENITEC BIOPHARMA INC | COM NEW | 1,850,000 | $24.75M | 0.22% | 00.0% | Unchanged | View |
| LENZLENZ THERAPEUTICS INC | COM | 4,178,823 | $23.74M | 0.21% | 00.0% | Unchanged | View |
| LXEOLEXEO THERAPEUTICS INC | COM | 5,000,000 | $23.28M | 0.20% | 00.0% | Unchanged | View |
| ACRVACRIVON THERAPEUTICS INC | COMMON STOCK | 12,229,396 | $21.77M | 0.19% | +3,888,888+46.6% | Added | View |
| ALTALTIMMUNE INC | COM NEW | 6,500,000 | $19.76M | 0.17% | +6,500,000 | New | View |
| KPTIKARYOPHARM THERAPEUTICS INC | COM NEW | 1,917,354 | $18.73M | 0.16% | 00.0% | Unchanged | View |
| DRUGBRIGHT MINDS BIOSCIENCES INC | COM NEW | 265,000 | $18.6M | 0.16% | 00.0% | Unchanged | View |
| AVTXAVALO THERAPEUTICS INC | COM NEW | 1,000,000 | $18.48M | 0.16% | +337,032+50.8% | Added | View |
| OKURONKURE THERAPEUTICS INC | COM CL A | 3,998,333 | $18.23M | 0.16% | 00.0% | Unchanged | View |
| FTHSENSEI BIOTHERAPEUTICS INC | COM NEW | 722,020 | $18.05M | 0.16% | +722,020 | New | View |
| AURAAURA BIOSCIENCES INC | COM | 2,500,000 | $17.75M | 0.15% | +2,500,000 | New | View |
| SABSSAB BIOTHERAPEUTICS INC | COM NEW | 4,401,500 | $17.17M | 0.15% | 00.0% | Unchanged | View |
| SPTXSEAPORT THERAPEUTICS INC | COMMON STOCK | 700,000 | $15.2M | 0.13% | +700,000 | New | View |
| PALIPALISADE BIO INC | COM | 7,124,116 | $14.89M | 0.13% | 00.0% | Unchanged | View |
| HLXCHELIX ACQUISITION CORP III | USD CL A ORD SHS | 1,250,000 | $13.3M | 0.12% | 00.0% | Unchanged | View |
| WAYWAYSTAR HLDG CORP | COM | 529,400 | $10.87M | 0.09% | 00.0% | Unchanged | View |
| EQEQUILLIUM INC | COM | 3,096,336 | $9.91M | 0.09% | 00.0% | Unchanged | View |
| MGNXMACROGENICS INC | COM | 1,864,176 | $8.61M | 0.07% | 00.0% | Unchanged | View |
| FRNMPERCEPTIVE CAP SOLUTIONS COR | CL A ORD SHS | 750,000 | $8.16M | 0.07% | 00.0% | Unchanged | View |
| ACETADICET BIO INC | COM NEW | 932,624 | $8.06M | 0.07% | −250,000−21.1% | Reduced | View |
| NAMSWNEWAMSTERDAM PHARMA COMPANY | *W EXP 11/22/202 | 333,333 | $7.12M | 0.06% | 00.0% | Unchanged | View |
| CRVSCORVUS PHARMACEUTICALS INC | COM | 450,000 | $6.72M | 0.06% | 00.0% | Unchanged | View |
| RANIRANI THERAPEUTICS HLDGS INC | COM CL A | 8,500,000 | $6.46M | 0.06% | 00.0% | Unchanged | View |
| JATTJATT II ACQUISITION CORP | ORD SHS | 500,000 | $5.68M | 0.05% | +500,000 | New | View |
| AMANAMANAT ACQUISITION CORP | CL A ORD | 375,000 | $3.81M | 0.03% | +375,000 | New | View |
| HOWLWEREWOLF THERAPEUTICS INC | COM | 2,387,744 | $859.35K | 0.01% | −4,293,563−64.3% | Reduced | View |
| PTNPALATIN TECHNOLOGIES INC | COM NEW | 62,124 | $670.32K | 0.01% | −7,876−11.3% | Reduced | View |
Sold out since Q1 2026 (18)
Positions held at the end of Q1 2026 that are no longer in this filing.
| Security | Class | Shares, Q1 2026 | Value, Q1 2026 | % of portfolio, Q1 2026 |
|---|---|---|---|---|
| ASNDASCENDIS PHARMA A/S | SPONSORED ADR | 10,281,496 | $2.35B | 24.92% |
| DNTHDIANTHUS THERAPEUTICS INC | COM | 2,611,733 | $219.18M | 2.32% |
| PRAXPRAXIS PRECISION MEDICINES I | COM NEW | 373,787 | $120.43M | 1.28% |
| SRPTSAREPTA THERAPEUTICS INC | COM | 3,902,596 | $84.92M | 0.90% |
| SYRESPYRE THERAPEUTICS INC | COM NEW | 1,621,620 | $81.79M | 0.87% |
| FULCFULCRUM THERAPEUTICS INC | COM | 6,053,960 | $46.43M | 0.49% |
| OLMAOLEMA PHARMACEUTICALS INC | COM | 2,600,000 | $38.77M | 0.41% |
| DSGNDESIGN THERAPEUTICS INC | COM | 2,972,973 | $31.63M | 0.34% |
| TVTXTRAVERE THERAPEUTICS INC | COM | 746,841 | $22.19M | 0.24% |
| GRALGRAIL INC | COM | 428,266 | $22.13M | 0.23% |
| RLMDRELMADA THERAPEUTICS INC | COM | 2,947,369 | $20.51M | 0.22% |
| STROSUTRO BIOPHARMA INC | COM SHS | 715,307 | $17.82M | 0.19% |
| CTNMCONTINEUM THERAPEUTICS INC | CL A | 1,296,012 | $16.93M | 0.18% |
| INSPINSPIRE MED SYS INC | COM | 325,663 | $16.8M | 0.18% |
| HNGEHINGE HEALTH INC | CL A | 364,613 | $14.06M | 0.15% |
| WGSGENEDX HOLDINGS CORP | COM CL A | 209,887 | $13.48M | 0.14% |
| RNAATRIUM THERAPEUTICS INC | COM | 864,102 | $11.55M | 0.12% |
| MPLTMAPLIGHT THERAPEUTICS INC | COM | 248,294 | $5.05M | 0.05% |
13F filings by quarter
| Quarter | Filed | Positions | Total value | Changes | Filing |
|---|---|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | 84 | $11.51B | vs. Q1 2026 | SEC |
| Q1 2026 | May 15, 2026 | 85 | $9.44B | vs. Q4 2025 | SEC |
| Q4 2025 | Feb 17, 2026 | 71 | $9.76B | vs. Q3 2025 | SEC |
| Q3 2025 | Nov 14, 2025 | 67 | $8.12B | vs. Q2 2025 | SEC |
| Q2 2025 | Aug 14, 2025 | 63 | $5.94B | vs. Q1 2025 | SEC |
| Q1 2025 | May 15, 2025 | 85 | $5.99B | vs. Q4 2024 | SEC |
| Q4 2024 | Feb 14, 2025 | 89 | $7.51B | vs. Q3 2024 | SEC |
| Q3 2024 | Nov 14, 2024 | 81 | $8.67B | vs. Q2 2024 | SEC |
| Q2 2024 | Aug 14, 2024 | 78 | $7.56B | vs. Q1 2024 | SEC |
| Q1 2024 | May 17, 2024Amended | 76 | $7.86B | vs. Q4 2023 | SECSEC |
| Q4 2023 | Feb 14, 2024 | 62 | $6.4B | vs. Q3 2023 | SEC |
| Q3 2023 | Nov 15, 2023Amended | 66 | $5.08B | vs. Q2 2023 | SECSEC |
| Q2 2023 | Aug 14, 2023 | 54 | $5.3B | vs. Q1 2023 | SEC |
| Q1 2023 | May 15, 2023 | 59 | $4.42B | vs. Q4 2022 | SEC |
| Q4 2022 | Feb 14, 2023 | 70 | $4.93B | vs. Q3 2022 | SEC |
| Q3 2022 | Nov 14, 2022 | 81 | $4.69B | vs. Q2 2022 | SEC |
| Q2 2022 | Aug 15, 2022 | 88 | $3.75B | vs. Q1 2022 | SEC |
| Q1 2022 | May 16, 2022 | 96 | $4.58B | vs. Q4 2021 | SEC |
| Q4 2021 | Feb 14, 2022 | 97 | $5.67B | vs. Q3 2021 | SEC |
| Q3 2021 | Nov 15, 2021 | 95 | $7.22B | vs. Q2 2021 | SEC |
| Q2 2021 | Aug 16, 2021 | 92 | $6.23B | vs. Q1 2021 | SEC |
| Q1 2021 | May 17, 2021 | 82 | $6.63B | – | SEC |